GlassScriptPhysician profile
Gregory C Dowling
NPI 1487916698
$9,383.01
in general payments reported to CMS, 2019-2025
58 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,411 · 2020: $1,206 · 2021: $1,241 · 2022: $978 · 2023: $1,173 · 2024: $1,767 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,546.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.48 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $871.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $818.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $809.28 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $617.60 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $430.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $412.62 | 2019-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $408.44 | 2019-2024 | Belsomra, Steglatro, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.42 | 2019-2025 | Jardiance |
| Allergan, INC. | $210.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.51 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $175.62 | 2019-2022 | |
| Amgen INC. | $174.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.66 | 2025 | Caplyta |
| Amarin Pharma, INC. | $159.72 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.